Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NCNO vs DBD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NCNO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)
NCNO Overall Winner
6-Pillar Tally: NCNO 4 – 2 DBD
Matrix Metrics: NCNO 6 – 4 DBD
As of Nov 17, 2026, nCino, Inc. (NCNO) is the stronger overall head-to-head candidate over Diebold Nixdorf, Incorporated (DBD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). NCNO carries a Unified Composite Score of 54.6/100 (HOLD) at $22.43 (22.2x Forward P/E, 8.2% operating margin), whereas DBD carries 41.7/100 (SELL) at $52.38 (8.6x Forward P/E, 9.0% operating margin).
- Technical & Structure Timing Caution: NCNO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile DBD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NCNO vs DBD
NCNO
Head-to-Head Winner
nCino, Inc. Common Stock
$22.43
-1.51% 1D
Market Cap
$2.4B
TTM Revenue
$622M
Forward P/E
22.2x
Beta / 30D Vol
0.40β · 38% Vol
Unified Composite Score
54.6
HOLD
Tech 38.0
Fund 53.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
DBD
Diebold Nixdorf, Incorporated
$52.38
-0.93% 1D
Market Cap
$1.8B
TTM Revenue
$3.92B
Forward P/E
8.6x
Beta / 30D Vol
1.03β · 59% Vol
Unified Composite Score
41.7
SELL
Tech 33.0
Fund 48.0
Flow 58.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NCNO 4 – 2 DBD)
1. Valuation Multiples
DBD
Forward P/E
22.2x
8.6x
Trailing P/E
71.1x
26.1x
PEG Ratio
N/M
N/M
EV / Revenue
4.3x
0.7x
2. Growth & Scale
NCNO
Revenue Growth (YoY)
+8.2%
+5.2%
Earnings Growth (YoY)
+147.6%
-82.9%
TTM Revenue (USD)
$622M
$3.92B
Market Cap
$2.4B
$1.8B
3. Profitability & Quality
DBD
Gross Margin
62.2%
26.0%
Operating Margin
8.2%
9.0%
Net Profit Margin
5.4%
2.0%
Return on Equity (ROE)
3.9%
7.7%
4. Balance Sheet & Cash Flow
NCNO
Cash Generation (TTM)
$132M
$127M
Cash Flow Margin
21.2%
3.2%
Net Cash / Leverage
$255M Net Debt (0.36x D/E)
$764M Net Debt (1.01x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NCNO
Options Structure Phase
CONSOLIDATION
BREAKDOWN
Current IV / %ile
55.7% (20th %ile)
45.7% (10th %ile)
Put/Call OI Skew
0.02x (Call-Skewed)
1.08x (Balanced)
OBV Trend / Tech Phase
DISTRIBUTION · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
NCNO
OpEx & R&D Intensity
54.0% of Rev ($336M)
17.0% of Rev ($667M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Software - Application Operator
Software - Application Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NCNO (6) vs DBD (4)| Institutional Metric | NCNO | DBD | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.4B | $1.8B | NCNO | |
| Trailing P/E Ratio | 71.1x | 26.1x | DBD | |
| Forward P/E Ratio | 22.2x | 8.6x | DBD | |
| Revenue Growth (YoY) | +8.2% | +5.2% | NCNO | |
| Operating Margin (TTM) | 8.2% | 9.0% | DBD | |
| Net Profit Margin | 5.4% | 2.0% | NCNO | |
| Return on Equity (ROE) | 3.9% | 7.7% | DBD | |
| 52-Week Range Position | 63% ($14–$28) | 2% ($52–$92) | NCNO | |
| Beta / 30D Volatility | 0.40β · 38% Vol | 1.03β · 59% Vol | NCNO | |
| Unified Institutional Score | 54.6 / 100 (HOLD) | 41.7 / 100 (SELL) | NCNO | |
| Trailing 12M Revenue (USD) | $622M | $3.92B | Scale | |
| Gross Profit Margin (TTM) | 62.2% | 26.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 4.3x EV/Rev | N/M PEG · 0.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $132M ($255M Net Debt (0.36x D/E)) | $127M ($764M Net Debt (1.01x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NCNO +32.73 pp
3M Horizon
NCNO +30.74 pp
6M Horizon
NCNO +72.9 pp
1Y Horizon
NCNO +7.44 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NCNO Revenue | DBD Revenue | NCNO Op. Margin | DBD Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $4.41B | N/A | -0.6% | DBD |
| FY2020 | $140M | $3.90B | -20.4% | 0.6% | DBD |
| FY2021 | $200M | $3.91B | -20.9% | 3.5% | DBD |
| FY2022 | $270M | $3.46B | -26.1% | -6.1% | DBD |
| FY2023 | $410M | N/A | -23.0% | N/A | NCNO |
| FY2024 | $480M | $3.75B | -8.3% | 4.9% | DBD |
| FY2025 | $540M | $3.81B | -3.4% | 6.4% | DBD |
| FY2026 | $590M | N/A | 0.6% | N/A | NCNO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NCNO
CONSOLIDATION
Current IV
55.7%
IV Percentile
20th %ile
Put/Call OI Skew
0.02x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NCNO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DBD
BREAKDOWN
Current IV
45.7%
IV Percentile
10th %ile
Put/Call OI Skew
1.08x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact DBD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NCNO Moat Profile
Cyclical / Execution-Driven Positioning
Software - Application Operator
OpEx & R&D Reinvestment
54.0% of Rev ($336M)
90D Engineering Disclosures
0 Published
DBD Moat Profile
Cyclical / Execution-Driven Positioning
Software - Application Operator
OpEx & R&D Reinvestment
17.0% of Rev ($667M)
90D Engineering Disclosures
0 Published
Investor FAQ NCNO vs DBD Key Questions & Quantitative Answers
As of Nov 17, 2026, nCino, Inc. (NCNO) is the stronger overall head-to-head candidate over Diebold Nixdorf, Incorporated (DBD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). NCNO carries a Unified Composite Score of 54.6/100 (HOLD) at $22.43 (22.2x Forward P/E, 8.2% operating margin), whereas DBD carries 41.7/100 (SELL) at $52.38 (8.6x Forward P/E, 9.0% operating margin). Technical & Structure Timing Caution: NCNO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.1); meanwhile DBD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NCNO leads the Growth & Scale pillar: NCNO posts +8.2% YoY revenue growth and +147.6% YoY earnings growth on $622M TTM revenue (62.2% gross margin, 8.2% operating margin), compared with DBD at +5.2% YoY revenue growth and -82.9% YoY earnings growth on $3.92B TTM revenue (26.0% gross margin, 9.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), NCNO cumulative revenue shifted +321.4% while DBD shifted -13.6%. In operating R&D and SG&A reinvestment, NCNO deploys 54.0% of Rev ($336M) (0 90-day corporate R&D disclosures) versus 17.0% of Rev ($667M) (0 disclosures) for DBD.
DBD screens cheaper on headline valuation multiples. NCNO trades at 22.2x Forward P/E, 71.1x Trailing P/E, N/M PEG, and 4.3x EV/Revenue (21.2% FCF margin), whereas DBD trades at 8.6x Forward P/E, 26.1x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (3.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NCNO (3.9% ROE) versus DBD (7.7% ROE) capital efficiency.
In options market volatility and institutional positioning, NCNO carries 55.7% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.40β · 38% Vol realized risk). By comparison, DBD carries 45.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.08x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.03β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DBD vs NCNO · Reverse Pair
NCNO vs GTM
· Sector Peer
NCNO vs FROG
· Sector Peer
NCNO vs BILL
· Sector Peer
DBD vs RPM
· Sector Peer
DBD vs PBI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem